Vaccitech (NASDAQ:VACC) Trading Down 4.2%

Vaccitech plc (NASDAQ:VACC)’s share price dropped 4.2% on Tuesday . The stock traded as low as $2.51 and last traded at $2.53. Approximately 18,050 shares were traded during trading, a decline of 93% from the average daily volume of 244,643 shares. The stock had previously closed at $2.64.

Vaccitech Trading Down 4.2 %

The firm has a market cap of $97.52 million, a price-to-earnings ratio of -1.77 and a beta of -0.40. The stock’s 50 day moving average is $2.75 and its 200 day moving average is $3.14.

Institutional Trading of Vaccitech

A number of institutional investors and hedge funds have recently made changes to their positions in VACC. Janney Montgomery Scott LLC acquired a new position in Vaccitech during the 3rd quarter worth approximately $46,000. Baird Financial Group Inc. increased its position in Vaccitech by 9.5% in the 2nd quarter. Baird Financial Group Inc. now owns 196,296 shares of the company’s stock valued at $404,000 after acquiring an additional 17,000 shares during the period. Millennium Management LLC increased its position in Vaccitech by 32.8% in the 4th quarter. Millennium Management LLC now owns 40,388 shares of the company’s stock valued at $97,000 after acquiring an additional 9,967 shares during the period. Renaissance Technologies LLC increased its position in shares of Vaccitech by 198.2% during the second quarter. Renaissance Technologies LLC now owns 34,000 shares of the company’s stock worth $70,000 after buying an additional 22,600 shares during the period. Finally, Citadel Advisors LLC acquired a new stake in shares of Vaccitech during the second quarter worth $31,000. Institutional investors own 26.13% of the company’s stock.

Vaccitech Company Profile

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer.